GSK begins cancer cell therapy tie-up with ImmaticsCancer biotech Immatics has begun a collaboration with GlaxoSmithKline to develop novel therapies built around its T-cell-based technology. Share XGSK begins cancer cell therapy tie-up with Immaticshttps://pharmaphorum.com/news/gsk-begins-cancer-cell-therapy-tie-up-with-immatics/
How cell and gene therapies are transforming pharma deal-makingAfter decades of clinical research targeting development of more “personalised” medicines, the biotechnology sector is now starting to Share XHow cell and gene therapies are transforming pharma deal-makinghttps://pharmaphorum.com/r-d/views-analysis-r-d/how-cell-and-gene-therapies-are-transforming-pharma-deal-making/
Kiadis sheds half its staff as lead cell therapy bombsDutch biotech Kiadis Pharma has abandoned its lead cell therapy and axed half its workforce after a failed Share XKiadis sheds half its staff as lead cell therapy bombshttps://pharmaphorum.com/news/kiadis-sheds-half-its-staff-as-lead-cell-therapy-bombs/
UK startup Ervaxx targets ‘dark matter’ of human genomeAfter two years in stealth mode, London-based biotech Ervaxx has officially launched with $17.5 million in first-round financing Share XUK startup Ervaxx targets ‘dark matter’ of human genomehttps://pharmaphorum.com/news/uk-startup-ervaxx-targets-dark-matter-of-human-genome/
Q&A: Adaptimmune’s Elliot Norry on cell therapyDr Elliot Norry, interim chief medical officer at Adaptimmune, discusses the unique challenges of cell therapy, from manufacturing Share XQ&A: Adaptimmune’s Elliot Norry on cell therapyhttps://pharmaphorum.com/views-analysis-market-access/qa-adaptimmune-elliot-norry-on-cell-therapy/
Building cell therapy leadership in EuropeIn these videos, Markwin Velders and Louis van de Wiel of Kite, a Gilead Company, provide a behind Share XBuilding cell therapy leadership in Europehttps://pharmaphorum.com/video/building-cell-therapy-leadership-europe/
Delivering innovative therapies with close industry-NHS partnershipsIt was a crucial moment when NHS England and the National Institute for Health and Care Excellence (NICE) Share XDelivering innovative therapies with close industry-NHS partnershipshttps://pharmaphorum.com/r-d/views-analysis-r-d/delivering-innovative-therapies-with-close-industry-nhs-partnerships/
Immunicum shares fall despite “fantastic” kidney cancer dataShares in Swedish biotech Immunicum dipped sharply after it reported phase 2 results with its lead dendritic cell Share XImmunicum shares fall despite “fantastic” kidney cancer datahttps://pharmaphorum.com/news/immunicum-shares-fall-despite-fantastic-kidney-cancer-data/
Celgene strikes $1.5bn cell therapy deal with ImmaticsCelgene shows no sign of slowing down on the deal-making front as its merger with Bristol-Myers Squibb draws Share XCelgene strikes $1.5bn cell therapy deal with Immaticshttps://pharmaphorum.com/news/celgene-strikes-1-5bn-cell-therapy-deal-with-immatics/
